All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | |- | [[Valsartan]] | Diovan | 6 | 2–4 hrs | 95% | 25% | 30/70% | Yes | 80–320 | Substrates: [[Multidrug resistance-associated protein 2|MRP2]] and [[OATP1B1|OATP1B1/SLCO1B1]] |- | [[Irbesartan]] | Avapro | 11–15 | 1.5–2 hrs | 90–95% | 70% | 20/80% | No | 150–300 | Minor substrates of [[CYP2C9]] |- | [[Telmisartan]] | Micardis | 24 | 0.5–1 hr | >99% | 42–58% | 1/99% | No | 40–80 | None known; >97% via biliary excretion |- | [[Eprosartan]] | Teveten | 5 | 1–2 hrs | 98% | 13% | 30/70% | No | 400–800 | None known; >90% via renal and biliary excretion |- | [[Olmesartan]] | Benicar/Olmetec | 14–16 | 1–2 hrs | >99% | 29% | 40/60% | No | 10–40 | Substrates of [[OATP1B1|OATP1B1/SLCO1B1]] |- | [[Azilsartan]] | Edarbi | 11 | 1.5–3 hrs | >99% | 60% | 55/42% | No | 40–80 | Minor substrates of CYP2C9 |- | [[Fimasartan]] | Kanarb | 7–11 | 0.5–3 hrs after dosing. | >97% | 30–40% | – | – | 30–120 | None known; primarily biliary excretion |- ! Drug ! Trade name ! [[Biological half-life]] [hrs] ! [[Cmax_(pharmacology)|Peak plasma concentration [Tmax] ]] ! [[Protein binding]] [%] ! [[Bioavailability]] [%] ! Renal/hepatic [[Clearance (medicine)|clearance]] [%] ! Food effect ! Daily dosage [mg] ! [[Metabolism]]/[[Transport protein|transporter]] |} |
| h Japanese (ja) | |- | [[Valsartan/ja|バルサルタン]] | Diovan | 6 | 2–4H | 95% | 25% | 30/70% | Yes | 80–320 | 基質: [[Multidrug resistance-associated protein 2/ja|MRP2]]と[[OATP1B1/ja|OATP1B1/SLCO1B1]] |- | [[Irbesartan/ja|イルベサルタン]] | Avapro | 11–15 | 1.5–2H | 90–95% | 70% | 20/80% | No | 150–300 | [[CYP2C9/ja|CYP2C9]]のマイナー基質 |- | [[Telmisartan/ja|テルミサルタン]] | Micardis | 24 | 0.5–1H | >99% | 42–58% | 1/99% | No | 40–80 | 不明; >97% 胆汁排泄 |- | [[Eprosartan/ja|エプロサルタン]] | Teveten | 5 | 1–2H | 98% | 13% | 30/70% | No | 400–800 | 不明; >90% 腎と胆汁排泄 |- | [[Olmesartan/ja|オルメサルタン]] | Benicar/Olmetec | 14–16 | 1–2H | >99% | 29% | 40/60% | No | 10–40 | [[OATP1B1/ja|OATP1B1/SLCO1B1]]の基質 |- | [[Azilsartan/jaZ|アジルサルタン]] | Edarbi | 11 | 1.5–3H | >99% | 60% | 55/42% | No | 40–80 | CYP2C9のマイナー基質 |- | [[Fimasartan/ja|フィマサルタン]] | Kanarb | 7–11 | 服用後0.5–3H | >97% | 30–40% | – | – | 30–120 | 不明; 主に胆汁性排泄 |- ! 薬剤 ! 製品名 ! [[Biological half-life/ja|半減期]] [時間] ! [[Cmax_(pharmacology)/ja|ピーク血漿中濃度[Tmax]]] ! [[Protein binding/ja|タンパク質結合率]] [%] ! [[Bioavailability/ja|生物学的利用能]] [%] ! 腎／肝[[Clearance (medicine)/ja|クリアランス]] [%] ! 食べ物の影響 ! 容量/日 [mg] ! [[Metabolism/ja|代謝]]/[[Transport protein/ja|トランスポーター]] |} |